Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.11.2010 | Brief Report

Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics

verfasst von: Monica Zuradelli, Bernard Peissel, Siranoush Manoukian, Daniela Zaffaroni, Monica Barile, Valeria Pensotti, Ugo Cavallari, Giovanna Masci, Frederique Mariette, Anne Caroline Benski, Armando Santoro, Paolo Radice

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions. Clinical, pathological, and family history data were collected from medical records and during genetic counseling sessions. All identified DH cases developed breast carcinoma and three of them were also diagnosed with ovarian carcinoma. Mean ages of breast and ovarian cancer diagnosis were 42.7 and 48.6 years, respectively. The majority of breast cancers showed a BRCA1-related phenotype, being negative for hormone receptors and HER2. Two cases reported different gastrointestinal tumors among relatives. Although the individuals described in this study show more severe clinical features in comparison to previously reported BRCA1 and BRCA2 DH cases, our observations support the hypothesis of a non specific phenotype of DH cases in terms of age of disease onset. In addition, our observations indicate that in DH patients breast carcinogenesis appears to be driven mainly by the mutations in BRCA1. The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses.
Literatur
1.
Zurück zum Zitat Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963–970CrossRefPubMed Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963–970CrossRefPubMed
2.
Zurück zum Zitat Struewing J, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200CrossRefPubMed Struewing J, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198–200CrossRefPubMed
3.
Zurück zum Zitat Roa B, Boyd A, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185–187CrossRefPubMed Roa B, Boyd A, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185–187CrossRefPubMed
4.
Zurück zum Zitat Oddoux C, Struewing J, Clayton C, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K (1996) The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188–190CrossRefPubMed Oddoux C, Struewing J, Clayton C, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K (1996) The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188–190CrossRefPubMed
5.
Zurück zum Zitat Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J (1998) Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol 70:432–434CrossRefPubMed Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J (1998) Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol 70:432–434CrossRefPubMed
6.
Zurück zum Zitat Friedman E, Bar-Sade Bruchim R, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, Peretz T, Lerer I, Wienberg N, Shushan A, Abeliovich AD (1998) Double heterozygotes from the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224–1227CrossRefPubMed Friedman E, Bar-Sade Bruchim R, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, Peretz T, Lerer I, Wienberg N, Shushan A, Abeliovich AD (1998) Double heterozygotes from the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224–1227CrossRefPubMed
7.
Zurück zum Zitat Gershoni-Baruch R, Dagan E, Kepten I, Freid G (1997) Co-segregation of BRCA1 185delAG mutation and BRCA2 6174delT in one single family. Eur J Cancer 33:2283–2284CrossRefPubMed Gershoni-Baruch R, Dagan E, Kepten I, Freid G (1997) Co-segregation of BRCA1 185delAG mutation and BRCA2 6174delT in one single family. Eur J Cancer 33:2283–2284CrossRefPubMed
8.
Zurück zum Zitat Peto J, Collins N, Barfoot R, Seals S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949CrossRefPubMed Peto J, Collins N, Barfoot R, Seals S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949CrossRefPubMed
9.
Zurück zum Zitat Loader S, Rowley PT (1998) Deleterious mutations of both BRCA1 and BRCA2 in three siblings. Genet Test 2:75–77CrossRefPubMed Loader S, Rowley PT (1998) Deleterious mutations of both BRCA1 and BRCA2 in three siblings. Genet Test 2:75–77CrossRefPubMed
10.
Zurück zum Zitat Ramus SJ, Friedman LS, Gayther SA, Ponder BA, Bobrow L, van der Looji M, Papp J, Olah E (1997) A breast/ovarian cancer patient with germilne mutations in both BRCA1 and BRCA2. Nat Genet 15:14–15CrossRefPubMed Ramus SJ, Friedman LS, Gayther SA, Ponder BA, Bobrow L, van der Looji M, Papp J, Olah E (1997) A breast/ovarian cancer patient with germilne mutations in both BRCA1 and BRCA2. Nat Genet 15:14–15CrossRefPubMed
11.
Zurück zum Zitat Liede A, Rehal P, Vesprini D, Jack E, Abrahamson J, Narod SA (1998) A breast cancer patient of Scottish descent with germline mutations in BRCA1 and BRCA2. Am J Hum Genet 62:1543–1544CrossRefPubMed Liede A, Rehal P, Vesprini D, Jack E, Abrahamson J, Narod SA (1998) A breast cancer patient of Scottish descent with germline mutations in BRCA1 and BRCA2. Am J Hum Genet 62:1543–1544CrossRefPubMed
12.
Zurück zum Zitat Tesoriero A, Andersen C, Southey M, Somers G, McKay M, Armes J, McCredie M, Giles G, Hopper JL, Venter D (1999) De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 65:567–569CrossRefPubMed Tesoriero A, Andersen C, Southey M, Somers G, McKay M, Armes J, McCredie M, Giles G, Hopper JL, Venter D (1999) De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 65:567–569CrossRefPubMed
13.
Zurück zum Zitat Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S (2000) An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin Genet 57:70–73CrossRefPubMed Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S (2000) An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin Genet 57:70–73CrossRefPubMed
14.
Zurück zum Zitat Bell DW, Erban J, Sgroi DC, Haber DA (2002) Selective loss oh heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res 62:2741–2743PubMed Bell DW, Erban J, Sgroi DC, Haber DA (2002) Selective loss oh heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res 62:2741–2743PubMed
15.
Zurück zum Zitat Caldes T, de la Hoya M, Tosar A, Sulleiro S, Godino J, Ibañez D, Martin M, Perez-Segura P, Diaz-Rubio E (2002) A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes. J Med Genet 39(8):44CrossRef Caldes T, de la Hoya M, Tosar A, Sulleiro S, Godino J, Ibañez D, Martin M, Perez-Segura P, Diaz-Rubio E (2002) A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes. J Med Genet 39(8):44CrossRef
16.
Zurück zum Zitat Choi DH, Lee MH, Bale AE, Carter D, Haffty BG (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638–1645CrossRefPubMed Choi DH, Lee MH, Bale AE, Carter D, Haffty BG (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638–1645CrossRefPubMed
17.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10.000 individuals. J Clin Oncol 20:1480–1490CrossRefPubMed Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10.000 individuals. J Clin Oncol 20:1480–1490CrossRefPubMed
18.
Zurück zum Zitat Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, Bancroft E, Salmon A, Barwell J, Eeles R, Oosterwijk JC (2005) Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet 42:e20CrossRefPubMed Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, de Hullu J, Hoogerbrugge N, Ligtenberg MJ, Ardern-Jones A, Bancroft E, Salmon A, Barwell J, Eeles R, Oosterwijk JC (2005) Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet 42:e20CrossRefPubMed
19.
Zurück zum Zitat Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293:964–969CrossRefPubMed Claus EB, Petruzella S, Matloff E, Carter D (2005) Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA 293:964–969CrossRefPubMed
20.
Zurück zum Zitat Musolino A, Naldi N, Michiara M, Bella MA, Zanelli P, Bortesi B, Cappelletti M, Savi M, Neri TM, Ardizzoni A (2005) A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 91:203–205CrossRefPubMed Musolino A, Naldi N, Michiara M, Bella MA, Zanelli P, Bortesi B, Cappelletti M, Savi M, Neri TM, Ardizzoni A (2005) A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 91:203–205CrossRefPubMed
21.
Zurück zum Zitat Smith M, Fawcett S, Sigalas E, Bell R, Devery S, Andrieska N, Winship I (2008) Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. Fam Cancer 7:119–124CrossRefPubMed Smith M, Fawcett S, Sigalas E, Bell R, Devery S, Andrieska N, Winship I (2008) Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. Fam Cancer 7:119–124CrossRefPubMed
22.
Zurück zum Zitat Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, Stacchiotti S, Terenziani M, Barbera F, Pasquini G, Frigerio S, Pierotti MA, Radice P, Della-Torre G (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43:601–606CrossRefPubMed Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, Stacchiotti S, Terenziani M, Barbera F, Pasquini G, Frigerio S, Pierotti MA, Radice P, Della-Torre G (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43:601–606CrossRefPubMed
23.
Zurück zum Zitat Caligo MA, Ghimenti C, Cipollini G, Ricci S, Brunetti I, Marchetti V, Olsen R, Neuhausen S, Shattuck-Eidens D, Conte PF, Skolnick MH, Bevilacqua G (1996) BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene 13:1483–1488PubMed Caligo MA, Ghimenti C, Cipollini G, Ricci S, Brunetti I, Marchetti V, Olsen R, Neuhausen S, Shattuck-Eidens D, Conte PF, Skolnick MH, Bevilacqua G (1996) BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene 13:1483–1488PubMed
24.
Zurück zum Zitat Baudi F, Quaresima B, Grandinetti C, Cuda G, Faniello C, Tassone P, Barbieri V, Bisegna R, Ricevuto E, Conforti S, Viel A, Marchetti P, Ficorella C, Radice P, Costanzo F, Venuta S (2001) Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Hum Mutat 18:163–164CrossRefPubMed Baudi F, Quaresima B, Grandinetti C, Cuda G, Faniello C, Tassone P, Barbieri V, Bisegna R, Ricevuto E, Conforti S, Viel A, Marchetti P, Ficorella C, Radice P, Costanzo F, Venuta S (2001) Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. Hum Mutat 18:163–164CrossRefPubMed
25.
Zurück zum Zitat Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M (2009) Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat. doi:10.1007/s10549-008-0190-3 Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M (2009) Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat. doi:10.​1007/​s10549-008-0190-3
26.
Zurück zum Zitat Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107–112 Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107–112
27.
Zurück zum Zitat Svendsen LB, Sønderggard JO, Bernstein IT, Bisgaard ML, Myrhøj T, Bülow S (1992) Hereditary non-polyposis colorectal cancer. Ugeskr Laeger 154(14):917–920PubMed Svendsen LB, Sønderggard JO, Bernstein IT, Bisgaard ML, Myrhøj T, Bülow S (1992) Hereditary non-polyposis colorectal cancer. Ugeskr Laeger 154(14):917–920PubMed
Metadaten
Titel
Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics
verfasst von
Monica Zuradelli
Bernard Peissel
Siranoush Manoukian
Daniela Zaffaroni
Monica Barile
Valeria Pensotti
Ugo Cavallari
Giovanna Masci
Frederique Mariette
Anne Caroline Benski
Armando Santoro
Paolo Radice
Publikationsdatum
01.11.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0853-8

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.